Related Image: Cells with double vision |
(Date:11/30/2009)..., N.J. - The inaugural Global Conference on Syste...2009, in Washington, DC, focuses on the convergenc...f critical importance to society. , The goal...arch activity around targeted complex systems, exa...s topic includes Critical Infrastructure Systems, ...
(Date:11/30/2009)... obstacle to HIV research is the virus,s exquisite...cientists, traditional tools, like the humble lab ...a team of researchers writing in BioMed Central,s ...nious assault on this problem by creating a mouse ...ng infected with HIV. , George Kassiotis, from t...
(Date:11/30/2009)... is a colorless and odorless radioactive gas that ...dium is a product of uranium decay and is found in...s, and groundwater as well as building materials, ...ncentration is expressed as the amount of radiatio...ducts in a liter of air; thus the units are picocu...
Breaking Biology News(10 mins):First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2A reductionist approach to HIV research 2Health Physics Society recommends considering action for indoor radon below current guidelines 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27Safe Ozone Levels May Not Be for Some 52829 1Safe Ozone Levels May Not Be for Some 52829 2(Date:11/30/2009)... , COLUMBUS, Ohio, Nov. 30 The...or one of the nation,s first minority business ear...n Cleveland December 3, is called "Transforming th...iness Early-Stage Capital Summit." It will feature...nority business leaders and local minority entrepr...
(Date:11/30/2009)... , KING OF PRUSSIA, Pa., Nov. 30 /PRNew... company specializing in interactive marketing se...today announced the launch of its HATCH Consultin.../hatch ). Aligning strategic experts across a ran...ing, the HATCH Consulting team is committed to gui...
(Date:11/30/2009)... , NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -...search (MJFF) today announced $1.5 million in tota...potentially disease-modifying therapies for Parkin...Novel Approaches to Drug Discovery for Parkinson,s...lan Corporation, plc (NYSE: ELN ), a neuroscienc...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNew...y guidance document for the publication of company...line today by the British Medical Journal (BMJ). "...on of the importance of providing support and guid...cation of study results in the peer-reviewed medic...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4Rabbit Anti-Methionine Aminopeptidase 2 Polyclonal Antibody, Unconjugated from Abcam
Anti-FKHR, phospho (Thr24) / FKHRL1, phospho (Thr32) Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Ricin communis Monoclonal Antibody, Unconjugated, Clone CP23 from Abcam
Kinase Buffer (10X) from Cell Signaling Technology
Biology Products: